Volixibat

Drug Profile

Volixibat

Alternative Names: LUM002; SAR-548304; SHP626; Volixibat potassium

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; Shire
  • Class Antihyperlipidaemics; Benzothiepins; Hepatoprotectants; Urea compounds
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • No development reported Cholestasis
  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 02 Feb 2017 Phase-II clinical trials in Non-alcoholic steatohepatitis in Canada (PO) (NCT02787304)
  • 02 Feb 2017 Phase-II clinical trials in Non-alcoholic steatohepatitis in United Kingdom (PO) (NCT02787304)
  • 11 Nov 2016 Pharmacodynamics data from a phase I trial in Non-alcoholic steatohepatitis (In volunteers) presented at The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top